Citable filing context
AZN's research view summarizes recent SEC filing context, starting with material_agreement from Oct 5, 2026.
| Filed | Item | Context |
|---|---|---|
| Oct 5, 2026 | material_agreement | AstraZeneca completed a $2 billion equity investment in Summit Therapeutics to accelerate ivonescimab development. |
| Oct 2, 2026 | material_agreement | AstraZeneca and Daiichi Sankyo entered into a clinical collaboration agreement with Summit Therapeutics to evaluate Datroway with ivonescimab. |
| Oct 1, 2026 | other | AstraZeneca admitted 9,828 further ordinary shares to trading on the London Stock Exchange under employee share schemes. |
| Feb 24, 2026 | business | AstraZeneca PLC is a global, innovation-driven biopharmaceutical company incorporated in England and Wales and headquartered in Cambridge, United Kingdom. The company operates across major therapeutic areas including Oncology, BioPharmaceuticals (Cardiovascular, Renal and Metabolism [CVRM], and Respiratory and Immunology), Vaccines and Immune Therapies, and Rare Diseases (following the 2021 acquisition of Alexion). Key marketed blockbusters driving product sales include Tagrisso, Imfinzi, Farxiga, Calquence, Lynparza, Ultomiris, and Fasenra. Geographically, AstraZeneca maintains a substantial commercial footprint distributed across the United States, Emerging Markets (led by China), Europe, and Established Rest of World (led by Japan). The company manages significant operational and financial variables, notably US gross-to-net deductions, which involve extensive accruals for contractual managed care rebates, Medicaid regulatory rebates, and wholesaler chargebacks. Key business risks include routine third-party challenges and invalidation proceedings against core product patents, potential generic and biosimilar erosion across major portfolios, and pricing pressures or mandatory price reductions in international markets. Additionally, the company faces evolving regulatory requirements, cybersecurity demands, and maintains limited, non-material distribution activities in Iran via third-party distributors. |
| Feb 24, 2026 | mda | AstraZeneca achieved total revenue of $58.7 billion in 2025, representing a 9% increase driven by robust commercial performance and strong pipeline delivery. Product sales reached $55.6 billion, bolstered by 16 blockbuster medicines, while alliance revenue grew 39% to $3.1 billion. Key commercial drivers included oncology, which rose 17% to $23.7 billion, and rare diseases, led by Ultomiris sales of $4.7 billion. Top-selling individual products included Farxiga at $8.5 billion, Tagrisso at $7.3 billion, and Imfinzi at $6.1 billion. Regionally, product sales increased 8% in the US to $23.4 billion, 11% in emerging markets to $15.1 billion, and 11% in Europe to $12.0 billion. Profitability improved significantly, with reported earnings per share rising to $6.60 and core earnings per share increasing 12% to $9.16. Operating profit reached $13.7 billion on a reported basis and $18.5 billion on a core basis. Cash generated from operating activities totaled $14.6 billion, while net debt decreased to $23.4 billion at year-end. Capital allocation prioritized R&D and strategic business development, including the acquisitions of EsoBiotec and SixPeaks Bio. For full-year 2026, AstraZeneca expects total revenue to increase by a mid-to-high single-digit percentage and core earnings per share to grow by a low double-digit percentage. |
| Feb 24, 2026 | risk_factors | AstraZeneca faces material risks across its product pipeline, including potential development failures, delayed clinical launches, and intense competition in therapy areas like immuno-oncology, which can erode patent exclusivity. Regulatory hurdles from agencies such as the FDA and EMA can delay approvals or mandate costly post-approval trials. Commercial operations confront complex global pricing pressures, driven by cost-containment measures like the US Inflation Reduction Act and the EU Joint Clinical Assessment, as well as economic instability in emerging markets. Supply chain vulnerabilities—including reliance on third-party active ingredient suppliers, single-source dependencies, and susceptibility to geopolitical conflicts or natural disasters—threaten manufacturing continuity and can lead to product shortages. The company is also exposed to cybersecurity threats, complex data protection and AI compliance mandates, and risks related to the illegal trade and counterfeiting of medicines. Legal and compliance exposures involve extensive product liability claims, ongoing governmental investigations, and intellectual property challenges, notably patent challenges and generic erosion. Finally, AstraZeneca operates within a volatile macroeconomic environment subject to foreign exchange fluctuations, global tax complexities, climate change physical risks, and potential failures to meet net-zero environmental targets or anti-bribery regulations. |
Source: SEC EDGAR filing text and events; period Oct 5, 2026; filed Oct 5, 2026.
AZN company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.